New U.S. study finds mRNA-1273.815, a monovalent vaccine targeting the Omicron XBB.1.5 variant, generates higher neutralizing antibody titers compared to its bivalent counterpart. The study supports updating to an XBB.1.5-based monovalent vaccine for the 2023-24 campaign to combat emerging variants.
Ultragenyx to seek accelerated approval for rare disease gene therapy
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
June 14, 2024